melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-14 and is reviewed periodically as new material appears.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
=== EC 1.6.99 With unknown physiological acceptors === EC 1.6.99.1: NADPH dehydrogenase EC 1.6.99.2: Now EC 1.6.5.2, NAD(P)H dehydrogenase (quinone EC 1.6.99.3: The activity is covered by EC 7.1.1.2, NADH:ubiquinone reductase (H+-translocating) EC 1.6.99.4: Now EC 1.18.1.2, ferredoxin—NADP+ reductase EC 1.6.99.5: Now EC 1.6.5.11, NADH dehydrogenase (quinone) EC 1.6.99.6: Now EC 1.6.5.10, NADPH dehydrogenase (quinone) EC 1.6.99.7: Now EC 1.5.1.34, 6,7-dihydropteridine reductase EC 1.6.99.8: Deleted EC 1.6.99.9: Now EC 1.16.1.4, cob(II)alamin reductase EC 1.6.99.10: included in EC 1.5.1.34, 6,7-dihydropteridine reductase EC 1.6.99.11: Deleted EC 1.6.99.12: Now EC 1.16.1.6, cyanocobalamin reductase (cyanide-eliminating) EC 1.6.99.13: Now EC 1.16.1.7, ferric-chelate reductase
Eccles, Jessica A.; Cadar, Dorina; Quadt, Lisa; Hakim, Alan J.; Gall, Nicholas; Bowyer, Vicky; Cheetham, Nathan; Steves, Claire J.; Critchley, Hugo D.; Davies, Kevin A. (2024). "Is joint hypermobility linked to self-reported non-recovery from COVID-19? Case–control evidence from the British COVID Symptom Study Biobank". BMJ Public Health. 2 (1) e000478. doi:10.1136/bmjph-2023-000478. PMC 11812800. PMID 40018183.
== Ectopic expression == Ectopic expression (CKBE) of the B (brain) type of creatine kinase (CK-BB) in red cells and platelets is a rare, benign anomaly detected during a newborn screening program for Duchenne muscular dystrophy.
Lloyd George and Balfour remained in government until the collapse of the coalition in October 1922. Under the new Conservative government, attempts were made to identify the background to and motivations for the declaration. A private Cabinet memorandum was produced in January 1923, providing a summary of the then-known Foreign Office and War Cabinet records leading up to the declaration. An accompanying Foreign Office note asserted that the primary authors of the declaration were Balfour, Sykes, Weizmann, and Sokolow, with "perhaps Lord Rothschild as a figure in the background", and that "negotiations seem to have been mainly oral and by means of private notes and memoranda of which only the scantiest records seem to be available." Following the 1936 general strike that was to degenerate into the 1936–1939 Arab revolt in Palestine, the most significant outbreak of violence since the Mandate began, a British Royal Commission – a high-profile public inquiry – was appointed to investigate the causes of the unrest. The Palestine Royal Commission, appointed with significantly broader terms of reference than the previous British inquiries into Palestine, completed its 404-page report after six months of work in June 1937, publishing it a month later. The report began by describing the history of the problem, including a detailed summary of the origins of the Balfour Declaration. Much of this summary relied on Lloyd-George's personal testimony; Balfour had died in 1930 and Sykes in 1919. He told the commission that the declaration was made "due to propagandist reasons ...
Both lightly and darkly pigmented skin contain similar numbers of melanocytes, with difference in skin color due to differences the packing of eumelanin into the melanosomes of keratinocytes: those in dark-toned skin are "packaged into peri-nuclear distributed, ellipsoid" melanosomes while those light-tone skin are "assembled into clustered small, circular melanosomes". There are also differences in the quantity and relative amounts of eumelanin and pheomelanin. Pigmentation including tanning is under hormonal control, including the MSH and ACTH peptides that are produced from the precursor proopiomelanocortin. Vitiligo is a skin disease where people lack melanin in certain areas in the skin. People with oculocutaneous albinism typically have a very low level of melanin production. Albinism is often but not always related to the TYR gene coding the tyrosinase enzyme. Tyrosinase is required for melanocytes to produce melanin from the amino acid tyrosine. Albinism may be caused by a number of other genes as well, like OCA2, SLC45A2, TYRP1, and HPS1 to name some. In all, already 17 types of oculocutaneous albinism have been recognized. Each gene is related to different protein having a role in pigment production. People with Chédiak–Higashi syndrome have a buildup of melanin granules due to abnormal function of microtubules.
Sources: en.wikipedia.org
In the years prior to UDI, white Rhodesians increasingly saw themselves as beleaguered and threatened, perpetually insecure and undermined by the metropole, unable to rely on anybody but themselves. The policy of "No independence before majority rule" transformed the white community's relationship with the UK and increased its suspicions of the British government's untrustworthiness and duplicity in colonial affairs, especially since the latter had adopted NIBMR as a formal policy – the very circumstance UDI was carried out to avoid, and which white Rhodesians had struggled to resist since the onset of decolonisation. Black nationalist parties reacted with outrage at UDI, with one ZANU official stating, "for all those who cherish freedom and a meaningful life, UDI has set a collision course that cannot be altered. 11 November 1965 [has] marked the turning point of the struggle for freedom in that land from a constitutional and political one to primarily a military struggle." It would, however, be several years before the nationalists adopted armed struggle as their primary strategy for obtaining political power. Violent tactics at this time were intended to create opportunities for external intervention, either by the international community or the British government, rather than seriously undermine the Rhodesian security forces. Because Rhodesian exports were generally competitive and had previously been entitled to preferential treatment on the British market, the former colony did not recognise the need for escalating the pace of diversification before independence.
== Discovery == Adiponectin was first characterised in 1995 in differentiating 3T3-L1 adipocytes (Scherer PE et al.). In 1996 it was characterised in mice as the mRNA transcript most highly expressed in adipocytes. In 2007, adiponectin was identified as a transcript highly expressed in preadipocytes (precursors of fat cells) differentiating into adipocytes. The human homologue was identified as the most abundant transcript in adipose tissue. Contrary to expectations, despite being produced in adipose tissue, adiponectin was found to be decreased in obesity. This downregulation has not been fully explained. The gene was localised to chromosome 3q27, a region highlighted as affecting genetic susceptibility to type 2 diabetes and obesity. Supplementation by differing forms of adiponectin was able to improve insulin control, blood glucose and triglyceride levels in mouse models. The gene was investigated for variants that predispose to type 2 diabetes. Several single nucleotide polymorphisms in the coding region and surrounding sequence were identified from several different populations, with varying prevalences, degrees of association and strength of effect on type 2 diabetes. Berberine, an isoquinoline alkaloid, has been shown to increase adiponectin expression, which partly explains its beneficial effects on metabolic disturbances. Mice fed the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have shown increased plasma adiponectin. Curcumin, capsaicin, gingerol, and catechins have also been found to increase adiponectin expression.
=== G04BE Drugs used in erectile dysfunction === G04BE01 Alprostadil G04BE02 Papaverine G04BE03 Sildenafil G04BE04 Yohimbin G04BE05 Phentolamine G04BE06 Moxisylyte G04BE07 Apomorphine G04BE08 Tadalafil G04BE09 Vardenafil G04BE10 Avanafil G04BE11 Udenafil G04BE30 Combinations G04BE52 Papaverine, combinations
=== Aortic regurgitation === Aortic regurgitation is treated with aortic valve replacement, which is recommended in patients with symptomatic severe aortic regurgitation. Aortic valve replacement is also recommended in patients that are asymptomatic but have chronic severe aortic regurgitation and left ventricular ejection fraction of less than 50%. Hypertension is treated in patients with chronic aortic regurgitation, with the anti-hypersensives of choice being calcium channel blockers, ACE inhibitors, or ARBs. Also, endocarditis prophylaxis is indicated before dental, gastrointestinal or genitourinary procedures. Mild to moderate aortic regurgitation should be followed with echocardiography and a cardiac stress test once every 1–2 years. In severe moderate/severe cases, patients should be followed with echocardiography and cardiac stress test and/or isotope perfusion imaging every 3–6 months.
Joy Osmanski as Paula Brooks / Tigress (season 3; recurring season 1; guest season 2):A member of the ISA who hunts the world's most dangerous humans. She is a gym teacher at Blue Valley High, the wife of "Crusher" Crock, and mother of Artemis Crock. In the second season, she breaks out of prison twice. In the third and final season, she moves in next door to the Whitmore-Dugans. Joel McHale as Sylvester Pemberton / Starman and Gerard Shugel / Ultra-Humanite (season 3; guest season 1; recurring season 2):A member of the original JSA who used an anti gravity Cosmic Staff invented by scientist Ted Knight that Courtney later finds. In the present, Ultra-Humanite forms an alliance with Icicle and Dragon King before transplanting his brain into Sylvester Pemberton's body in order to manipulate Stargirl and her JSA, and Dragon King's brain into Ultra-Humanite's albino gorilla body for him to "defeat" as Starman alongside Jordan's son before intending to run for president as a mouthpiece for Icicle to spread his ideals.
Sources: en.wikipedia.org
=== Shadowhunters === Cordelia Carstairs — a Shadowhunter arriving in London trying to make powerful friends in order to save her family from disgrace. She is brave, loyal, selfless, and determined, and wields the mythical sword known as Cortana. She has been in love with James since the two were children. Unlike her older brother, Alastair, she is well-liked by the other characters. She has long dark red hair, black eyes, and light brown skin. James Herondale — Cordelia's childhood friend and crush, who is very popular and handsome. He is intelligent and introverted, and struggles with his demonic heritage on his mother's side. He has the ability to travel into the shadow realm, though he has difficulty controlling this ability. While he falls in love with Cordelia, he has been in love with Grace for several years due to the fact that she is manipulating his emotions with the help of a seemingly harmless bracelet he has worn for a while. He has pale skin, black hair, and gold eyes. Lucie Herondale — Cordelia's soon-to-be parabatai and James's younger sister. Lucie is a lively young girl who is very talkative, protective, and friendly. She is an aspiring writer and writes an ongoing novel known as "The Beautiful Cordelia", which she sends to Cordelia to read every month. She has the ability to see all kinds of ghosts and command them to do her bidding. She has pale skin, brown hair, and blue eyes. Matthew Fairchild — James's parabatai, who is cheerful, flirtatious, and sometimes considered scandalous by many of the London Shadowhunters.
JRT is the analogue of the lysergamide lysergic acid diethylamide (LSD) in which the embedded tryptamine structure within the ergoline ring system of LSD has been replaced with an isotryptamine structure. Hence, JRT is not an ergoline, lysergamide, or tryptamine itself, but could be considered a cyclized isotryptamine. JRT exists as four enantiomers, including (+)-JRT and (–)-JRT, with (+)-JRT being the active enantiomer and the form used in scientific research.
=== Gas chromatography-combustion-IRMS === The gas chromatography-combustion-IRMS is a way to detect any variations in the isotopic composition of an organic compound from the standard. This test is used to detect whether or not synthetic testosterone was consumed, leading to an increased abnormal testosterone/epitestosterone (T/E) level. Assumptions:
==== Bill 124 ==== In 2019, the government passed Bill 124, which limited public sector salary increases to one percent for each of the next three years. After a legal challenge from unions, it was struck down as unconstitutional in November 2022 by the Ontario Superior Court of Justice, a decision upheld by the Court of Appeal for Ontario in February 2024. Afterwards, Premier Ford said that the law would be repealed.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.